Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 8/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.50 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465740 | 0.91 | ABL1 (0.62) | ABL1MEN1KMT2ARAB9ARORC | |
| SCHEMBL1464619 | 0.90 | ABL1 (0.56) | ABL1MEN1KMT2ARORCALDH1A1 | |
| SCHEMBL3959750 | 0.90 | MEN1 (0.48) | ABL1MEN1KMT2APHGDHPSMD14 | |
| SCHEMBL1464724 | 0.87 | KDM1A (0.62) | ABL1MEN1KMT2ARORCALDH1A1 | |
| SCHEMBL1464766 | 0.87 | ABL1 (0.57) | ABL1MEN1KMT2ARAB9ARORC | |
| SCHEMBL1464341 | 0.85 | ALDH1A1 (0.58) | ABL1MEN1KMT2APHGDHRORC | |
| SCHEMBL1465202 | 0.85 | PAX8 (0.61) | ABL1MEN1KMT2ARAB9ARORC | |
| SCHEMBL1464404 | 0.85 | KDM1A (0.60) | ABL1MEN1KMT2APHGDHRORC | |
| SCHEMBL12095615 | 0.85 | ABL1 (0.44) | ABL1MEN1KMT2APHGDHRAB9A | |
| SCHEMBL1465790 | 0.85 | ABL1 (0.55) | ABL1MEN1KMT2ARAB9ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | claimed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | claimed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| EP-2081905-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008014199-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ABL1 2388/4885MEN1 4811/4885KMT2A 3627/4885 |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | CNR2, CNR1, OPRL1 | ABL1 2287/4885MEN1 4811/4885KMT2A 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.